Stokes Hubbell Capital Management buys $2,140,671 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Stokes Hubbell Capital Management scooped up 742 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 20, 2016. The investment management firm now holds a total of 34,853 shares of AbbVie Inc which is valued at $2,140,671.AbbVie Inc makes up approximately 0.97% of Stokes Hubbell Capital Management’s portfolio.

AbbVie Inc opened for trading at $61.3 and hit $61.99 on the upside on Friday, eventually ending the session at $61.42, with a gain of 0.08% or 0.05 points. The heightened volatility saw the trading volume jump to 51,03,024 shares. Company has a market cap of $98,962 M.

Other Hedge Funds, Including , Reilly Financial Advisors reduced its stake in ABBV by selling 50 shares or 1.76% in the most recent quarter. The Hedge Fund company now holds 2,788 shares of ABBV which is valued at $171,239. AbbVie Inc makes up approx 0.04% of Reilly Financial Advisors’s portfolio.North American Management Corp boosted its stake in ABBV in the latest quarter, The investment management firm added 350 additional shares and now holds a total of 12,197 shares of AbbVie Inc which is valued at $725,843. AbbVie Inc makes up approx 0.12% of North American Management Corp’s portfolio.Charter Trust Co reduced its stake in ABBV by selling 383 shares or 0.24% in the most recent quarter. The Hedge Fund company now holds 160,376 shares of ABBV which is valued at $9,381,996. AbbVie Inc makes up approx 1.15% of Charter Trust Co’s portfolio.Rathbone Brothers Plc reduced its stake in ABBV by selling 19,320 shares or 11.78% in the most recent quarter. The Hedge Fund company now holds 144,718 shares of ABBV which is valued at $8,466,003. AbbVie Inc makes up approx 0.52% of Rathbone Brothers Plc’s portfolio.

On the company’s financial health, AbbVie Inc reported $1.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 29, 2016. Analyst had a consensus of $1.12. The company had revenue of $6400.00 million for the quarter, compared to analysts expectations of $6382.82 million. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.89 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.